Patents by Inventor Raphael Clynes
Raphael Clynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092911Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: ApplicationFiled: August 18, 2023Publication date: March 21, 2024Applicant: Bristol-Myers Squibb CompanyInventors: James NOVOTNY, Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
-
Patent number: 11806555Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: July 19, 2022Date of Patent: November 7, 2023Assignee: The Trustees of Columbia University in the City of New YorkInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 11807686Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: GrantFiled: May 30, 2018Date of Patent: November 7, 2023Assignee: Bristol-Myers Squibb CompanyInventors: James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
-
Publication number: 20230111697Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: ApplicationFiled: April 6, 2022Publication date: April 13, 2023Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20230074793Abstract: Provided herein, in certain aspects, are methods of treating a cancer in a subject, comprising administering a bispecific anti-CTLA4Ă—anti-PD1 antibody to the subject.Type: ApplicationFiled: August 5, 2022Publication date: March 9, 2023Applicant: XENCOR, INC.Inventors: Barbara HICKINGBOTTOM, Paul FOSTER, Raphael CLYNES, Ying DING, Lei BAO, Catherine AVERSA-FLEENER
-
Publication number: 20230043374Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: ApplicationFiled: July 19, 2022Publication date: February 9, 2023Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 11512122Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.Type: GrantFiled: May 15, 2020Date of Patent: November 29, 2022Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
-
Patent number: 11298570Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: March 12, 2019Date of Patent: April 12, 2022Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20210261666Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-Ll positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.Type: ApplicationFiled: May 30, 2018Publication date: August 26, 2021Applicant: Bristol-Myers Squibb CompanyInventors: James NOVOTNY, JR., Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
-
Patent number: 10994157Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: February 20, 2020Date of Patent: May 4, 2021Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20210070824Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.Type: ApplicationFiled: May 15, 2020Publication date: March 11, 2021Inventors: Matthew Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
-
Publication number: 20200237635Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: ApplicationFiled: February 20, 2020Publication date: July 30, 2020Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20190262250Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: ApplicationFiled: March 12, 2019Publication date: August 29, 2019Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 10265258Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: August 4, 2017Date of Patent: April 23, 2019Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20190072541Abstract: The presently disclosed subject matter relates to biomarkers allowing for improved diagnosis and prognosis of alopecia areata as well as effective treatments for the disease, including methods that incorporate biomarkers capable of identifying patient sub-populations that will respond to such treatments and methods that incorporate biomarkers capable of tracking the progress of such treatments.Type: ApplicationFiled: August 15, 2016Publication date: March 7, 2019Inventors: Angela Christiano, Raphael Clynes
-
Publication number: 20180291378Abstract: The presently disclosed subject matter relates, in certain embodiments, to compositions and methods for the inhibition of the JAK-STAT pathway in order to induce hair growth. In certain embodiments, the presently disclosed subject matter relates to topical treatments with small molecule inhibitors of the JAK-STAT pathway to induce hair growth.Type: ApplicationFiled: May 9, 2016Publication date: October 11, 2018Inventors: Angela Christiano, Raphael Clynes
-
Patent number: 9895301Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: August 7, 2015Date of Patent: February 20, 2018Assignee: The Trustees of Columbia University in The City of New YorkInventors: Angela M. Christiano, Raphael Clynes
-
Publication number: 20180021235Abstract: The invention provides for methods for treating a hiar loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: ApplicationFiled: August 4, 2017Publication date: January 25, 2018Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 9763866Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: March 10, 2016Date of Patent: September 19, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 9737469Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: March 10, 2016Date of Patent: August 22, 2017Assignee: The Trustees of Columbia University in the City of New YorkInventors: Angela M. Christiano, Raphael Clynes